Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NAOV 
NanoVibronix Inc (NAOV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: NAOV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -91.87% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.02M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) - | Beta 1.76 | 52 Weeks Range 0.67 - 9.47 | Updated Date 06/29/2025 |
52 Weeks Range 0.67 - 9.47 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -210.82% | Operating Margin (TTM) -180.68% |
Management Effectiveness
Return on Assets (TTM) -12.08% | Return on Equity (TTM) -28.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6327332 | Price to Sales(TTM) 1.14 |
Enterprise Value 6327332 | Price to Sales(TTM) 1.14 | ||
Enterprise Value to Revenue 2.38 | Enterprise Value to EBITDA 0.43 | Shares Outstanding 2584840 | Shares Floating 2584473 |
Shares Outstanding 2584840 | Shares Floating 2584473 | ||
Percent Insiders 3.22 | Percent Institutions 2.31 |
Upturn AI SWOT
NanoVibronix Inc
Company Overview
History and Background
NanoVibronix, Inc. was founded to develop noninvasive therapeutic devices utilizing its proprietary surface acoustic wave (SAW) technology. The company has focused on commercializing pain and wound healing products.
Core Business Areas
- PainShield: The PainShield product line utilizes low-intensity ultrasonic energy to provide pain relief for musculoskeletal conditions.
- UroShield: The UroShield product is designed to prevent catheter-associated urinary tract infections (CAUTIs) through the use of ultrasonic vibrations.
Leadership and Structure
The leadership team consists of Brian Murphy (CEO) and other key executives. The company operates with a functional organizational structure focusing on product development, sales, and marketing.
Top Products and Market Share
Key Offerings
- PainShield: PainShield is a surface acoustic wave (SAW) device for pain relief. Market share is relatively small but growing in the non-opioid pain management sector. Competitors include conventional pain medications (opioids, NSAIDs) and other non-invasive pain relief devices from companies like Becton Dickinson.
- UroShield: UroShield aims to reduce CAUTIs. Market share is increasing as CAUTI prevention becomes a larger focus, but still represents a small percentage of the infection prevention market. Competitors include antimicrobial catheters produced by Bard and Teleflex.
Market Dynamics
Industry Overview
The medical device industry is highly competitive and regulated. The pain management market is growing with a shift toward non-opioid therapies. The infection control market is driven by hospital-acquired infection (HAI) reduction efforts.
Positioning
NanoVibronix is a niche player focusing on innovative non-invasive solutions within the pain management and infection prevention spaces. Their competitive advantage lies in their patented SAW technology.
Total Addressable Market (TAM)
The total addressable market for pain management and infection prevention is estimated to be billions of dollars. NanoVibronix is positioned to capture a portion of this TAM through its unique technology.
Upturn SWOT Analysis
Strengths
- Proprietary SAW technology
- Non-invasive treatment solutions
- Potential for recurring revenue (consumables)
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Small sales and marketing team
- Dependence on third-party distributors
- Need for further clinical validation
Opportunities
- Expansion into new geographic markets
- Development of new applications for SAW technology
- Partnerships with larger medical device companies
- Increasing awareness of non-opioid pain management options
Threats
- Competition from established medical device companies
- Reimbursement challenges from payers
- Regulatory hurdles
- Risk of technological obsolescence
Competitors and Market Share
Key Competitors
- BDX
- BSX
- TFX
Competitive Landscape
NanoVibronix competes with larger, more established medical device companies. NanoVibronix's advantage lies in its unique SAW technology, while its disadvantage is its limited resources.
Growth Trajectory and Initiatives
Historical Growth: Growth has been gradual, driven by increased adoption of PainShield and UroShield.
Future Projections: Future growth depends on expanding market penetration, securing favorable reimbursement, and successful product development.
Recent Initiatives: Recent initiatives include expanding distribution networks and pursuing clinical studies to validate product efficacy.
Summary
NanoVibronix is a company with innovative technology but faces challenges related to financial resources and competition. Their SAW technology provides a competitive edge in the non-invasive pain management and infection prevention markets. Increasing market penetration, securing favorable reimbursement, and developing new products will be critical for future success. Close monitoring of regulatory hurdles and competition is necessary.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, Investor presentations, Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and competitor information are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NanoVibronix Inc
Exchange NASDAQ | Headquaters Tyler, TX, United States | ||
IPO Launch date 2017-06-27 | CEO & Director Dr. Doron Robert Besser M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 31 | Website https://www.nanovibronix.com |
Full time employees 31 | Website https://www.nanovibronix.com | ||
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Tyler, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.